Skip to main content

Table 3 BNP/NT-proBNP (pg/ml) levels at baseline and end of follow-up in the BNP-guided therapy group and symptom-guided therapy group

From: B-type natriuretic peptide-guided therapy for heart failure (HF): a systematic review and meta-analysis of individual participant data (IPD) and aggregate data

BNP/NT-proBNP (pg/ml)*

Studies that provided IPD

Studies that provided aggregate data

 
 

Anguita [20]

Northstar [27]

Shochat [32]

Starbrite [31]

Upstep [34]

Christchurch Pilot [29]

Time-CHF [26, 33]

Berger [21]

Prima [22]

Signal-HF [25]

Battlescarred [28]

Stars-BNP [23]

Protect [30]

Guide-It [11]

 

n = 60

n = 407

n = 120

n = 130

n = 268

n = 69

n = 499

n = 278

n = 345

n = 252

n = 364

n = 220

n = 151

 

BNP guided-therapy:

Baseline*

34 (7, 83)

1884 (1385, 2955)

1905 (1099, 4488)

453 (221, 1135)

601 (346, 946)

1839

HFrEF

3998

(2075, 7220)

HFpEF

2210

(1514–4081)

2216 (355, 9649)

2961

(discharge)

(1383, 5144)

2661 (2.1)

2012 (516, 10,233)

352 (260)

2344

2568

End of follow-up

8 (3, 83)

–

1765 (476, 3966)

413 (111, 894)

–

1169

–

–

2529

2360

1610 (6 months)

284

(180)

(3 months)

1125

1209

Difference

2 (−31, 28)

–

−81 (− 1273, 512)

−14 (− 461, 248)

–

− 670

–

–

− 432 (− 1392, 297)

−301

−402

− 68

1219

1359

% change from baseline:

6%

–

−4%

−3%

–

−36%

–

–

−15%

− 11%

− 20%

− 19%

−52%

− 53%

Symptom-guided therapy:

Baseline*

22 (5, 104)

2042 (1390, 3560)

1569 (784, 4919)

441 (189, 981)

609 (376, 952)

2127

HFrEF

4657

(2455, 7520)

HFpEF

2191

(1478, 4890)

2469

(355, 18,487)

2936 (discharge)

(1291, 5525)

2429 (2.1)

1996 (425, 6588)

–

1946

2678

End of follow-up

39

(6, 104)

–

1822

(618, 4489)

471

(236, 1180)

–

2102

–

–

2364

2067

1537

(6 months)

–

1844

1397

Difference

4 (−20, 46)

–

73 (− 554, 1245)

51 (− 130, 288)

–

−25

–

–

− 572 (− 1329, 434)

− 362

− 459

–

102

1281

% change from baseline:

18%

–

5%

12%

–

−1%

–

–

−19.5%

− 15%

−23%

–

−5%

− 48%

  1. *Median (IQR) reported for all studies except Christchurch Pilot (type of summary statistic not reported), Protect (median only reported), Signal-HF (geometric mean reported), and Stars-BNP (mean reported)
  2. For all studies, BNP values at discharge from randomisation visit were used (assumed values at discharge reported if not stated otherwise in trial reports)
  3. For Northstar and Upstep, BNP values at the end of follow-up were not available. For the remaining studies providing IPD, the difference between the baseline and end of follow-up was calculated as the median (IQR) change from baseline across patients. For studies providing aggregate data, the change from baseline was calculated by taking the average BNP at end of follow-up from the average BNP at baseline.
  4. For all studies, the % change from baseline is calculated as the average difference as a percentage of the average baseline BNP
Back to article page

Systematic Reviews

ISSN: 2046-4053